BR112022022003A2 - Método para aprimorar imunogenicidade de antígeno de proteína/peptídeo - Google Patents
Método para aprimorar imunogenicidade de antígeno de proteína/peptídeoInfo
- Publication number
- BR112022022003A2 BR112022022003A2 BR112022022003A BR112022022003A BR112022022003A2 BR 112022022003 A2 BR112022022003 A2 BR 112022022003A2 BR 112022022003 A BR112022022003 A BR 112022022003A BR 112022022003 A BR112022022003 A BR 112022022003A BR 112022022003 A2 BR112022022003 A2 BR 112022022003A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide antigen
- protein
- immunogenicity
- enhance protein
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
MÉTODO PARA APRIMORAR IMUNOGENICIDADE DE ANTÍGENO DE PROTEÍNA/PEPTÍDEO. Trata-se de um método para aprimorar a imunogenicidade de um antígeno de proteína/peptídeo, em que o método compreende conjugar um antígeno de proteína/peptídeo com um açúcar para formar um conjugado de antígeno de glicoproteína/peptídeo, que aprimorou a imunogenicidade em comparação com um antígeno de proteína/peptídeo não conjugado. Em particular, o método envolve conjugar um patógeno, tal como um antígeno de proteína de superfície viral ou um fragmento do mesmo, com um polissacarídeo, em particular um polissacarídeo capsular de Streptococcus pneumoniae. O conjugado com imunogenicidade aprimorada pode ser usado para prevenir ou tratar doenças causadas por patógenos, em particular doenças causadas por coronavírus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010369100 | 2020-05-01 | ||
PCT/CN2021/090809 WO2021219047A1 (zh) | 2020-05-01 | 2021-04-29 | 一种增强蛋白/肽抗原免疫原性的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022022003A2 true BR112022022003A2 (pt) | 2022-12-13 |
Family
ID=78373348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022022003A BR112022022003A2 (pt) | 2020-05-01 | 2021-04-29 | Método para aprimorar imunogenicidade de antígeno de proteína/peptídeo |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230330220A1 (pt) |
EP (1) | EP4144365A1 (pt) |
JP (1) | JP2023526780A (pt) |
KR (1) | KR20230005313A (pt) |
CN (1) | CN115484977A (pt) |
AU (1) | AU2021262999A1 (pt) |
BR (1) | BR112022022003A2 (pt) |
CA (1) | CA3176745A1 (pt) |
MX (1) | MX2022013456A (pt) |
WO (1) | WO2021219047A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2023863B1 (en) * | 2019-09-20 | 2021-05-25 | Univ Griffith | Protein particles and uses thereof |
CN114699521B (zh) * | 2022-06-07 | 2023-02-24 | 中国人民解放军军事科学院军事医学研究院 | 基于金属硫蛋白家族的免疫佐剂及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192540A (en) | 1988-04-19 | 1993-03-09 | American Cyanamid Company | Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine |
JP2002513028A (ja) * | 1998-04-28 | 2002-05-08 | ガレニカ ファーマシューティカルズ, インコーポレイテッド | ポリサッカリド抗原結合体 |
AU2004220590B2 (en) | 2003-03-07 | 2010-02-18 | Inhibitex, Inc. | Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
NZ567164A (en) | 2005-10-18 | 2012-06-29 | Novavax Inc | Functional influenza virus like particles (VLPS) |
WO2013022808A2 (en) * | 2011-08-05 | 2013-02-14 | The University Of Chicago | Immunogenic protein conjugates and methods for making and using the same |
CN106075428A (zh) * | 2015-07-01 | 2016-11-09 | 北京科兴中维生物技术有限公司 | 一种免疫原性组合物及其制备方法 |
EP3347042A4 (en) * | 2015-09-10 | 2019-02-20 | Inventprise, LLC. | MULTIVALENT CONJUGATES WITH VIRUSUAL PARTICLES |
JP2020500007A (ja) | 2016-10-13 | 2020-01-09 | マサチューセッツ インスティテュート オブ テクノロジー | ジカウイルスエンベロープタンパク質に結合する抗体およびその使用 |
CN108619502A (zh) * | 2017-03-22 | 2018-10-09 | 武汉博沃生物科技有限公司 | 一种基于重组载体蛋白的季节流感-rsv-流脑联合疫苗 |
CA3061709A1 (en) * | 2017-03-28 | 2018-10-04 | The Children's Medical Center Corporation | A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof |
GB201802339D0 (en) * | 2018-02-13 | 2018-03-28 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
-
2021
- 2021-04-29 AU AU2021262999A patent/AU2021262999A1/en active Pending
- 2021-04-29 EP EP21797065.6A patent/EP4144365A1/en active Pending
- 2021-04-29 JP JP2022566202A patent/JP2023526780A/ja active Pending
- 2021-04-29 WO PCT/CN2021/090809 patent/WO2021219047A1/zh unknown
- 2021-04-29 BR BR112022022003A patent/BR112022022003A2/pt unknown
- 2021-04-29 US US17/922,335 patent/US20230330220A1/en active Pending
- 2021-04-29 CN CN202180030064.4A patent/CN115484977A/zh active Pending
- 2021-04-29 MX MX2022013456A patent/MX2022013456A/es unknown
- 2021-04-29 KR KR1020227041681A patent/KR20230005313A/ko active Search and Examination
- 2021-04-29 CA CA3176745A patent/CA3176745A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230330220A1 (en) | 2023-10-19 |
AU2021262999A1 (en) | 2023-01-19 |
WO2021219047A1 (zh) | 2021-11-04 |
MX2022013456A (es) | 2022-11-16 |
CA3176745A1 (en) | 2021-11-04 |
EP4144365A1 (en) | 2023-03-08 |
JP2023526780A (ja) | 2023-06-23 |
CN115484977A (zh) | 2022-12-16 |
KR20230005313A (ko) | 2023-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022022003A2 (pt) | Método para aprimorar imunogenicidade de antígeno de proteína/peptídeo | |
AR125327A2 (es) | Composiciones de neisseria meningitidis y métodos de las mismas | |
BR112018075198A2 (pt) | método para o tratamento de câncer ou uma doença associada a patógeno, composição farmacêutica, e kit | |
MX2022014125A (es) | Anticuerpos y conjugados de los mismos. | |
PE20190398A1 (es) | Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos | |
BR112017009398A2 (pt) | moléculas de ligação específicas para cd73 e seus usos | |
MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
MX2022012685A (es) | Compuestos específicos contra la proteína s de coronavirus y usos de los mismos. | |
BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
NO20072733L (no) | Doseformer | |
CL2015001900A1 (es) | Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina. | |
ECSP12011685A (es) | Inmunoconjugados dirigidos | |
ES2530428T3 (es) | Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos | |
MY192248A (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
UA107929C2 (en) | Antibodies against cxcr4 for the treatment of hiv infection | |
BR112015008418A2 (pt) | uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae | |
AR092896A1 (es) | Composiciones inmunogenicas | |
BR112014013640A2 (pt) | anticorpos úteis na imunização passiva contra influenza | |
BR112014014605A2 (pt) | moléculas de anticorpo de ligação de trombina e usos das mesmas | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
BR112019008844A2 (pt) | conjugado de proteína de polissacarídeo imunogênico compreendendo um polissacarídeo derivado de b. streptococcus gbs | |
MX2018008078A (es) | Tecnologia de sinergismo anticuerpo-farmaco para el tratamiento de enfermedades. | |
BR112022011885A2 (pt) | Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia | |
BR112018007121A2 (pt) | anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv | |
BR112018017174A2 (pt) | conjugados de aminoácido e peptídeo e processo de conjugação |